F-Prime Capital — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesForesite CapitalGV (Google Ventures)HongShan Capital Group+1 more
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inAnthony Quinn(Director)
Board seatCatherine Stehman-Breen· per SEC Form D · $100.4M raise · filed Mar 2018
Co-investorsAtlas VentureForesite CapitalInvus
Unison Investment Management (UnisonIM) is a registered investment adviser that builds and manages institutional equity and credit strategies giving exposure to U.S. residential housing and home price appreciation.
FintechPropTechSan Francisco, US
Thomas Sponholtz(Founder, CEO & Chairman)John Martinez(Director)Edgar Green(Director)James Riccitelli(Executive Officer, Director)Douglas H. Lowrey(Director)Matthew O'Hara(Chief Investment Officer)
Board seatDavid Jegen· per SEC Form D · $40M raise · filed Jun 2018
Cambridge, US
James P. Dougherty(Executive Officer, Director)Jerry Held(Director)Archibald Cox(Director)
BoardGary Rieschel(Director)
Co-investorsRaptor Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.